Researchers test the therapeutic efficacy of potential COVID-19 interventions in mouse models Aarthi Narayanan, Associate Professor, and Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), are conducting three studies to assess the therapeutic efficacy of candidate interventions for COVID-19 in mouse models. For the first study, the researchers hope to determine the survival advantage conferred by a therapeutic. Related Stories For this study, the researchers are infecting ACE2 animals intranasally with SARS-CoV-2 and following them for up to seven days after infection. As part of the second study, they are working to determine the survival advantage conferred by a therapeutic if an alternate course or dosing strategy needs to be followed. Again, the researchers are following the animals for up to seven days after infection.